MedTrace Logo

Erythropoietin Role in Acute Kidney Injury

NCT03401710 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 134

Last updated 2021-12-28

No results posted yet for this study

Summary

The use of erythropoietin to treat anemia in acute kidney injury (AKI) is controversial. No previous clinical trial has assessed the possible reduction of transfusions when erythropoietin is started very early in a setting of in-hospital acute kidney injury.

This randomised multicenter pragmatic clinical trial will compare the need for transfusion in acute kidney injury between two groups: group 1 will receive erythopoietin 4000 UI every other day and group 2 the usual treatment.

Conditions

  • Anemia Renal

Interventions

DRUG

Erythropoietin

Erythropoietin 4000 UI will be administered every other day subcutaneously

Sponsors & Collaborators

  • Saint-Joseph University

    lead OTHER

Principal Investigators

  • Mabel Aoun, MD · Saint-Joseph University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-16
Primary Completion
2021-03-20
Completion
2021-08-25

Countries

  • Lebanon

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03401710 on ClinicalTrials.gov